Evaxion A (EVAX) Revenue (2024 - 2025)
Evaxion A's (EVAX) quarterly Revenue came in at -$1000.0 in Q4 2025, down 100.82% on a YoY basis from $122000.0 in Q4 2024, and down 100.01% quarter-over-quarter from $7.5 million in Q3 2025.
Powered by 
Analysis
Evaxion A (EVAX) Revenue (2024 - 2025) Analysis & Trends
Evaxion A (EVAX) has reported Revenue for 2 consecutive years, with -$1000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Revenue fell 100.82% year-over-year to -$1000.0; the trailing twelve-month figure through Jun 2026 stood at $7.5 million (up 135.86% YoY), and the FY2025 full-year result was $7.5 million, up 125.12% from the prior year.
- Revenue fell to -$1000.0 in Q4 2025 per EVAX's latest filing, from $7.5 million in the prior quarter.
- Across five years, Revenue topped out at $7.5 million in Q3 2025 and bottomed at -$1000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Evaxion A | 21.12 Mn | 7.12 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | 7.49 Mn |
| Jun 30, 2025 | 37,000.00 |
| Dec 31, 2024 | 122,000.00 |
| Sep 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | 51,000.00 |